1Furlant M,Brollo L,Lugatti E,et al.Pharmacokinetic aspects of Levofloxcin 500mg once daily during sequential intravenous/oral therapy inpatients with lower respiratory tract infections[J].Antimicrob chemother,2003,51(1):101-106.
2Furst M,Lamb HM.Levofloxcin.An updated review of bacterial infection[J],Drug,2002,62(5):2127-2167.
3Frank E,Liu J,Kinasewitz G,et al,A muster,open-labeled randomized comparison of Levofloxcin and azithromycin plus ceftriaxone hospitalized adults with moderate to severe community-acquired pneumonia[J],Clin.Ther,2002,24:1292-1308.
4Mandell Bartlett JG,Dowell SF,et al.Update of practice guidelines for management of community-acquired pneumonia in immunocompet ent adults[J].Clin infect Dis,2003,37(2):1405-1433.
8Murakami K,Suzuki C,Fujii A,et al.Intravenous immunoglobulin prevents release of proinflammatory cytokines in human monocytic cells stimulated with procalcitonin[J].Inflamm Res,2012,61(6):617-622.
